Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido

Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido

  • July 29, 2026

Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.

Leave A Comment

Fields (*) Mark are Required